FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur.The rare disease space has always been uniquely difficult for drug development, but recent regulatory developments are shaking things up. There have been signs of both positive and negative movement in this space. Laksheet Johari, an analyst for […]
